Eli Lilly's Next Weight Loss Drug: What to Know

If you're following the weight loss drug space, you've probably noticed Eli Lilly keeps making headlines. The company already markets Mounjaro (tirzepatide) for type 2 diabetes and Zepbound for obesity, and both have delivered impressive clinical results. But Lilly isn't stopping there.

A new compound called orforglipron is moving through late-stage clinical trials, and early data suggests it could be one of the most convenient and potent weight loss medications ever developed. Here's what the science shows, what the timeline looks like, and what this means if you're making treatment decisions right now.

What Is Orforglipron?

Orforglipron is a GLP-1 receptor agonist, the same class of drug as Ozempic and Wegovy. GLP-1 stands for glucagon-like peptide-1, a hormone your body naturally produces to regulate blood sugar and appetite. Drugs in this class mimic that hormone, helping you feel fuller longer and reducing overall calorie intake.

What makes orforglipron different is its structure. Current GLP-1 medications like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are peptide-based, meaning they are made from chains of amino acids. Because peptides break down in the digestive system, these drugs must be injected.

Orforglipron is a small-molecule GLP-1 receptor agonist. Small molecules can survive the digestive process, which means orforglipron is taken as a simple daily pill, with no injection required and no refrigeration needed.

What Does the Early Data Show?

Phase 2 trial results published in the New England Journal of Medicine in 2023 showed meaningful promise. In one trial involving people with obesity, participants taking the highest dose of orforglipron lost an average of around 14.7% of their body weight over 36 weeks. That's a clinically significant result for an oral medication.

For context, the injectable semaglutide (Wegovy) produced average weight loss of roughly 15% in its major trial over 68 weeks. Tirzepatide (Zepbound) produced up to 20-22% average weight loss at the highest dose in its trials.

Orforglipron's phase 2 numbers are not a direct apples-to-apples comparison. Different trial designs, durations, and populations make direct comparisons tricky. But the early signal is strong enough that the drug earned fast-track designation from the FDA and advanced into phase 3 trials.

Key Phase 3 Trials to Watch

Eli Lilly launched a broad phase 3 program called ATTAIN for orforglipron in obesity and ACHIEVE for type 2 diabetes. Results from several of these trials are expected to read out in 2025 and 2026. Those results will determine whether Lilly files for FDA approval.

Why an Oral Option Could Change Access

One of the biggest barriers to GLP-1 treatment today isn't clinical, it's practical. Many patients are hesitant about weekly injections. Others live in areas where temperature-controlled medication storage is difficult. And some people simply prefer a pill to a shot.

If orforglipron reaches approval with comparable efficacy to injectable options, it could bring GLP-1 therapy to a much larger group of people who have avoided treatment for those practical reasons.

There's also a potential cost implication. Small-molecule drugs are generally cheaper to manufacture than peptide-based biologics. That doesn't guarantee lower prices at the pharmacy counter, especially early after launch, but it does create more flexibility for generic competition down the road. Biologics like semaglutide face a longer path to generics than small molecules do.

That said, any meaningful price relief from orforglipron is likely years away, even if everything goes perfectly in trials.

How Does It Compare to Zepbound and Wegovy?

Here's a side-by-side look at where orforglipron stands compared to the two leading injectable options, based on available clinical data.

A few important notes about this table. Orforglipron's weight loss figure comes from a shorter phase 2 trial, and weight loss with GLP-1 drugs typically continues to accumulate over time. Final phase 3 numbers could look different, higher or lower. Also, Zepbound targets two hormonal pathways (GLP-1 and GIP), which is likely why it shows stronger results than single-pathway drugs. Orforglipron targets only GLP-1.

What About Side Effects?

The side effect profile of orforglipron in phase 2 trials looked broadly similar to other GLP-1 medications. The most common complaints were gastrointestinal, including nausea, vomiting, diarrhea, and constipation. These effects were most common during dose escalation and tended to lessen over time.

One thing researchers are watching closely in phase 3 is whether daily oral dosing creates a different pattern of side effects compared to weekly injections. Weekly injections create a peak-and-trough drug level in the blood. A daily pill may produce a steadier drug level, which could mean either better tolerability or different symptom patterns. Phase 3 data will answer this more definitively.

As with all GLP-1 medications, standard precautions apply. Orforglipron is not appropriate for people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. Your prescriber will review your full medical history before any GLP-1 therapy.

What This Means for the Competitive Landscape

From a patient perspective, increased competition in the GLP-1 space is a good thing. More approved options mean more negotiating power for insurers, more reasons for manufacturers to compete on price, and more choices for patients who don't respond well to one medication.

Novo Nordisk, the maker of Wegovy and Ozempic, is also developing its own oral semaglutide for obesity under the name Rybelsus-plus programs, and the company already has an oral semaglutide (Rybelsus) approved for type 2 diabetes. Both companies are racing to dominate the oral GLP-1 market.

For patients currently on injectable GLP-1 medications, this competitive pressure may eventually translate into better coverage, lower out-of-pocket costs, and wider availability. If you're already navigating high costs for your current prescription, checking the GLP-1 Coupons page is a practical step you can take right now, while the pipeline drugs work their way toward approval.

Should You Wait for Orforglipron?

This is probably the most common question patients will have, and the honest answer is: almost certainly not.

Orforglipron is not approved. Phase 3 data hasn't fully reported. Even if the results are strong and Lilly files for approval promptly, FDA review typically takes 12 months or more. A realistic best-case scenario for a US launch would be late 2026 or 2027, and that assumes no delays in trials, the FDA review, or manufacturing scale-up.

Obesity and metabolic disease are not conditions where waiting is without cost. If you are eligible for a GLP-1 medication now, the health benefits of starting treatment, reduced cardiovascular risk, improved blood sugar control, lower blood pressure, and sustained weight loss, begin accumulating from day one of treatment.

The drugs available today are well-studied, FDA-approved, and already helping millions of people. Putting your health on hold to wait for a potentially better pill that may be two-plus years away is a decision that carries real risk.

If you're unsure which medication or provider is right for you, comparing your options through a resource like the Best Providers page is a practical starting point. A qualified prescriber can help you match your medical history, preferences, and coverage to the right current option.